Eledon pharmaceuticals announces use of tegoprubart anti-cd40l antibody in second-ever transplant of genetically modified heart from a pig to a human

Landmark cardiac xenotransplantation procedure conducted at university of maryland medical center tegoprubart, administered investigationally to prevent organ rejection post-transplant, targets the cd40l pathway known to play an essential role in both innate and adaptive immune cell activation and function. irvine, calif.
ELDN Ratings Summary
ELDN Quant Ranking